A Phase 2/3, Randomized, Double-blind, Placebo- and Active- controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease (GALAXI).

  • Sparrow, Miles (Primary Chief Investigator (PCI))
  • Hogg, Julie (Project Manager)

Project: Research

StatusActive
Effective start/end date4/10/1830/06/21